Alphonsus H. C. Ng

TL;DR: This review, which summarizes developments in microfluidics-based immunoassays since 2000, includes four sections, focusing on the configurations of immuno ASSays that have been implemented in micro fluidics, the main fluid handling modalities that have be used for microfluidity immunoASSays, multiplexed immunoAssays in micro fluididic platforms, and the emergence of label-free detection techniques.

TL;DR: A model of tumor epitope immunogenicity was developed that filtered out 98% of non-immunogenic peptides with a precision above 0.70 and was validated in an independent cohort of 310 epitopes prioritized from tumor sequencing data and assessed for T cell binding.

TL;DR: The first particle-based immunoassay on DMF without the aid of oil carrier fluid to enable droplet movement is reported, allowing the realization of a novel on-chip particle separation and resuspension method capable of removing greater than 90% of unbound reagents in one step.

TL;DR: It is proposed that this new platform paves the way for a benchtop tool that is useful for implementing immunoassays in near-patient settings, including community hospitals, physicians' offices, and small clinical laboratories.

TL;DR: A compact and portable, field-deployable, point-of-care system relying on digital microfluidics that can rapidly test a small volume of capillary blood for disease-specific antibodies for measles and rubella is described.